Institutional members access full text with Ovid®

Share this article on:

CENTRAL SEROUS CHORIORETINOPATHY IN PATIENTS RECEIVING EXOGENOUS TESTOSTERONE THERAPY

Nudleman, Eric MD, PhD*; Witmer, Matthew T. MD; Kiss, Szilard MD; Williams, George A. MD*,‡; Wolfe, Jeremy D. MD*,‡

doi: 10.1097/IAE.0000000000000198
Original Study

Purpose: To report an association between central serous chorioretinopathy (CSCR) and exogenous testosterone therapy.

Methods: This is a retrospective case series from two institutions. Patients who presented with fluorescein angiography and optical coherence tomography findings consistent with CSCR were included. All patients were concurrently being treated with exogenous testosterone therapy and lacked other known risk factors for CSCR.

Results: Nine patients presented with CSCR after beginning exogenous testosterone therapy. Two patients stopped therapy with resolution of symptoms and subretinal fluid.

Conclusion: Exogenous testosterone may be an independent risk factor for the development of CSCR.

Exogenous testosterone therapy for the treatment of low testosterone has become increasingly prevalent. We report nine patients who presented with central serous chorioretinopathy after starting testosterone therapy. Two patients discontinued therapy with anatomical and symptomatic resolution. We propose a potential role for exogenous testosterone in the pathology of central serous chorioretinopathy.

*Associated Retinal Consultants, Royal Oak, Michigan;

Department of Ophthalmology, Weill Cornell Medical College, New York, New York; and

Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Beaumont Eye Institute, Royal Oak, Michigan.

Reprint requests: Jeremy D. Wolfe, MD, Associated Retinal Consultants, 3535 W, 13 Mile Road, Royal Oak, MI 48073; e-mail: jwolfe@arcpc.net

Supported by a departmental grant from Research to Prevent Blindness (M.T.W. and S.K.).

None of the authors have any conflicting interests to disclose.

© 2014 by Ophthalmic Communications Society, Inc.